prednisolone + diphenhydramine

VP1301 is an investigational fixed-dose combination therapy developed by Vanda Pharmaceuticals, comprising the corticosteroid prednisolone and the first-generation antihistamine diphenhydramine. It is currently in clinical development for the prevention and treatment of motion sickness. The therapeutic rationale for this combination involves leveraging diphenhydramine's established anti-emetic and anti-vertiginous properties—mediated through its antagonism of Histamine H1 and muscarinic acetylcholine receptors—alongside the potential modulatory effects of prednisolone on the vestibular system or central emetic pathways. By targeting multiple pathways involved in the development of motion-induced nausea and vomiting, VP1301 aims to provide superior efficacy compared to existing monotherapies.

Other names

prednisolone/diphenhydramine